vs
Cronos Group Inc.（CRON）与Mind Medicine (MindMed) Inc.（DFTX）财务数据对比。点击上方公司名可切换其他公司
Cronos Group Inc.的季度营收约是Mind Medicine (MindMed) Inc.的49.2倍（$44.5M vs $906.0K）。Cronos Group Inc.净利率更高（-4.1% vs -2634.0%，领先2629.9%）。Cronos Group Inc.同比增速更快（47.0% vs -16.1%）
Cronos集团是全球性大麻素企业，主营大麻种植、加工及相关衍生产品的分销业务，产品线覆盖健康补充剂、快消品及医用大麻品类，主要服务北美、欧洲、亚太地区的合规娱乐与医用消费市场，严格遵循各地监管要求保障产品品质。
Definium Therapeutics（前称MindMed）是一家总部位于纽约的生物技术企业，专注于致幻剂及更广泛的精神可塑性药物的临床与治疗应用开发，在中枢神经药物研发领域深耕相关创新疗法的落地潜力。
CRON vs DFTX — 直观对比
营收规模更大
CRON
是对方的49.2倍
$906.0K
营收增速更快
CRON
高出63.1%
-16.1%
净利率更高
CRON
高出2629.9%
-2634.0%
损益表 — Q4 2025 vs Q4 2023
| 指标 | | |
|---|---|---|
| 营收 | $44.5M | $906.0K |
| 净利润 | $-1.8M | $-23.9M |
| 毛利率 | 36.4% | — |
| 营业利润率 | -16.8% | -2450.8% |
| 净利率 | -4.1% | -2634.0% |
| 营收同比 | 47.0% | -16.1% |
| 净利润同比 | -104.2% | -386.7% |
| 每股收益（稀释后） | $-0.01 | $-0.58 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CRONDFTX
| Q4 25 | $44.5M | — | ||
| Q3 25 | $36.3M | — | ||
| Q2 25 | $33.5M | — | ||
| Q1 25 | $32.3M | — | ||
| Q4 24 | $30.3M | — | ||
| Q3 24 | $34.3M | — | ||
| Q2 24 | $27.8M | — | ||
| Q1 24 | $25.3M | — |
净利润CRONDFTX
| Q4 25 | $-1.8M | — | ||
| Q3 25 | $26.0M | — | ||
| Q2 25 | $-39.7M | — | ||
| Q1 25 | $6.1M | — | ||
| Q4 24 | $43.7M | — | ||
| Q3 24 | $8.3M | — | ||
| Q2 24 | $-8.8M | — | ||
| Q1 24 | $-2.2M | — |
毛利率CRONDFTX
| Q4 25 | 36.4% | — | ||
| Q3 25 | 50.4% | — | ||
| Q2 25 | 43.4% | — | ||
| Q1 25 | 42.6% | — | ||
| Q4 24 | 35.7% | — | ||
| Q3 24 | 10.5% | — | ||
| Q2 24 | 22.7% | — | ||
| Q1 24 | 17.7% | — |
营业利润率CRONDFTX
| Q4 25 | -16.8% | — | ||
| Q3 25 | -1.4% | — | ||
| Q2 25 | -15.9% | — | ||
| Q1 25 | -12.6% | — | ||
| Q4 24 | -37.5% | — | ||
| Q3 24 | -98.2% | — | ||
| Q2 24 | -56.1% | — | ||
| Q1 24 | -63.1% | — |
净利率CRONDFTX
| Q4 25 | -4.1% | — | ||
| Q3 25 | 71.4% | — | ||
| Q2 25 | -118.7% | — | ||
| Q1 25 | 19.0% | — | ||
| Q4 24 | 144.3% | — | ||
| Q3 24 | 24.4% | — | ||
| Q2 24 | -31.5% | — | ||
| Q1 24 | -8.9% | — |
每股收益（稀释后）CRONDFTX
| Q4 25 | $-0.01 | — | ||
| Q3 25 | $0.07 | — | ||
| Q2 25 | $-0.10 | — | ||
| Q1 25 | $0.02 | — | ||
| Q4 24 | $0.12 | — | ||
| Q3 24 | $0.02 | — | ||
| Q2 24 | $-0.02 | — | ||
| Q1 24 | $-0.01 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $831.8M | $99.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.1B | $78.1M |
| 总资产 | $1.2B | $124.5M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CRONDFTX
| Q4 25 | $831.8M | — | ||
| Q3 25 | $824.2M | — | ||
| Q2 25 | $834.4M | — | ||
| Q1 25 | $837.8M | — | ||
| Q4 24 | $858.8M | — | ||
| Q3 24 | $862.0M | — | ||
| Q2 24 | $848.2M | — | ||
| Q1 24 | $855.1M | — |
股东权益CRONDFTX
| Q4 25 | $1.1B | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | $1.1B | — | ||
| Q2 24 | $1.1B | — | ||
| Q1 24 | $1.1B | — |
总资产CRONDFTX
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $1.2B | — | ||
| Q4 24 | $1.2B | — | ||
| Q3 24 | $1.2B | — | ||
| Q2 24 | $1.1B | — | ||
| Q1 24 | $1.1B | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $11.8M | $-20.6M |
| 自由现金流经营现金流 - 资本支出 | $9.7M | — |
| 自由现金流率自由现金流/营收 | 21.8% | — |
| 资本支出强度资本支出/营收 | 4.8% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $149.0K | — |
8季度趋势，按日历期对齐
经营现金流CRONDFTX
| Q4 25 | $11.8M | — | ||
| Q3 25 | $13.3M | — | ||
| Q2 25 | $2.8M | — | ||
| Q1 25 | $-2.1M | — | ||
| Q4 24 | $7.7M | — | ||
| Q3 24 | $11.6M | — | ||
| Q2 24 | $1.7M | — | ||
| Q1 24 | $-2.2M | — |
自由现金流CRONDFTX
| Q4 25 | $9.7M | — | ||
| Q3 25 | $8.8M | — | ||
| Q2 25 | $-1.0M | — | ||
| Q1 25 | $-17.4M | — | ||
| Q4 24 | $4.2M | — | ||
| Q3 24 | $5.2M | — | ||
| Q2 24 | $1.0M | — | ||
| Q1 24 | $-3.9M | — |
自由现金流率CRONDFTX
| Q4 25 | 21.8% | — | ||
| Q3 25 | 24.3% | — | ||
| Q2 25 | -3.0% | — | ||
| Q1 25 | -53.8% | — | ||
| Q4 24 | 13.8% | — | ||
| Q3 24 | 15.1% | — | ||
| Q2 24 | 3.7% | — | ||
| Q1 24 | -15.5% | — |
资本支出强度CRONDFTX
| Q4 25 | 4.8% | — | ||
| Q3 25 | 12.3% | — | ||
| Q2 25 | 11.5% | — | ||
| Q1 25 | 47.3% | — | ||
| Q4 24 | 11.7% | — | ||
| Q3 24 | 18.7% | — | ||
| Q2 24 | 2.6% | — | ||
| Q1 24 | 6.8% | — |
现金转化率CRONDFTX
| Q4 25 | — | — | ||
| Q3 25 | 0.51× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.34× | — | ||
| Q4 24 | 0.18× | — | ||
| Q3 24 | 1.39× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CRON
| Cannabis Flower | $33.7M | 76% |
| Cannabis Extracts | $10.8M | 24% |
DFTX
暂无分部数据
